share_log

百时美施贵宝KRAS抑制剂再获FDA批准

JRJ Finance ·  Jun 21 19:41

据美国食品药品管理局,百时美施贵宝的重磅KRAS G12C抑制剂Krazati再获加速批准,与西妥昔单抗联合使用,治疗经美国FDA批准的检测确定为KRAS G12C突变的局部晚期或转移性结直肠癌成年患者,这些患者之前曾接受过氟嘧啶、奥沙利铂和伊立替康为基础的化疗。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment